Product Portfolio


AP102 is a somatostatin analogue treatment for acromegaly currently in pre-clinical development. Unlike other somatostatins analogues that are currently used to treat acromegaly patients for whom surgery is not an option, AP102 has a balanced, dual action specifically on somatostatin receptors 2 and 5 and has been observed in early research to reduce human pituitary growth hormone secretion while having little impact on blood sugar levels and propensity to cause diabetes.

These findings will be the subject of future research in human subjects to confirm the safety and efficacy of AP102 starting in 2018.

Medical Vials